Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00424242 · ClinicalTrials.gov registry record · Early Phase 1
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
A Early Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
NCT00424242 is a Early Phase 1 study that has completed, run by Northwestern University. The registered enrollment target is 15 participants.
The verdict
NCT00424242, a Early Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Pemetrexed disodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Studying samples of cerebrospinal fluid and blood from patients with cancer in the laboratory may help doctors learn how pemetrexed disodium works in the body and identify biomarkers related to cancer. PURPOSE: This clinical trial is studying the side effects and how well pemetrexed disodium works in treating patients with leptomeningeal metastases.
Interventions
- DRUG Pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00424242
The ClinicalTrials.gov registry entry for NCT00424242 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pemetrexed is the first listed.
NCT00424242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00424242 about?
NCT00424242 is a clinical study titled "Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases". RATIONALE: Pemetrexed disodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Studying samples of cerebrospinal fluid and blood from patients with cancer in the laboratory may help doctors learn how pemetrexed disodium works in the body and identify bioma...
What is the current status of trial NCT00424242?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2007-01. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00424242?
The interventions under investigation include: Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00424242?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.